MCE 的所有產品僅用作科學研究，我們不為任何個人用途提供產品和服務。

CAS No. : 162359-55-9

MCE 國際站：Fingolimod

產品活性：Fingolimod 是一種 1-磷酸鞘氨醇 (sphingosine 1-phosphate，S1P) 拮抗劑，作用于 K562 和 NK 細胞，IC₅₀ 為 0.033 nM。Fingolimod 還是一種 pak1 激活劑，免疫抑制劑。

研究領域：GPCR/G Protein  |  Cytoskeleton  |  Cell Cycle/DNA Damage

作用靶點：LPL Receptor  |  PAK

In Vitro: The monocyte-derived immature dendritic cells (iDCs) are pretreated with various concentrations of S1P for various periods of time prior to their incubation with NK cells. Four hours incubation of autologous or allogeneic iDCs with 0.2-20 μM of S1P significantly protectes these cells from NK cell lysis. The IC₅₀ values of S1P are calculated at 160 nM for autologous iDCs, and 34 nM for allogeneic iDCs. Next, the inhibitory effect of S1P is revered by various concentrations of Fingolimod or SEW2871, with an IC₅₀ effect of 173 or 15 nM, respectively. Fingolimod has been reported to reduce LPA synthesis via inhibition of the lysophospholipase autotaxin. Fingolimod treatment correlates with a significant elevation of axonal cAMP, a crucial factor for axonal outgrowth. Additionally, Fingolimod significantly reduces LPA levels in the injured nerve. PF-8380 treatment correlates with improved myelin thickness.

In Vivo: Fingolimod treatment results in significantly increased nerve conduction at 14 days post-crush in wildtype C57BL/6 mice. However, Foxn1^-/- mice, which are devoid of T- but not B-lymphocytes, show an improvement of nerve regeneration under fingolimod treatment. Although the mean increase in nerve conduction velocity in both fingolimod-treated and controlFoxn1^-/- mice implies a potentially positive role of T-lymphocyte deficiency on nerve regeneration, only fingolimod-treated Foxn1^-/- mice show a significant improvement compared to C57BL/6 controls and performed better in the functional analysis. Treatment of the animals with Fingolimod for 28 d results in a clear reduction in the binding of ¹⁸F-GE180 when compare with vehicle-treated animals and evaluated by ex vivo autoradiography. Quantification of the binding of the radiotracer revealed a significant reduction in the binding potential of ¹⁸F-GE180 (P<0.0001) after treatment with Fingolimod.

相關產品：FDA-Approved Drug Library Plus  |  Drug Repurposing Compound Library  |  FDA-Approved Drug Library Mini  |  Anti-Aging Compound Library  |  Kinase Inhibitor Library  |  GPCR/G Protein Compound Library  |  CNS-Penetrant Compound Library  |  Anti-COVID-19 Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Cell Cycle/DNA Damage Compound Library  |  Drug Repurposing Compound Library Plus  |  Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Fingolimod hydrochloride  |  PF-3758309  |  Ki16425  |  FRAX486  |  BMS-986020  |  Ozanimod  |  PF-543 Citrate  |  5-Aminosalicylic Acid  |  IPA-3  |  PF429242 dihydrochloride  |  TY-52156  |  G-5555  |  AM966  |  Etrasimod  |  AM095  |  FRAX1036  |  FRAX597  |  NVS-PAK1-1  |  Amiselimod hydrochloride  |  Cenerimod  |  LPA2 antagonist 1  |  FTY720 (S)-Phosphate  |  KPT-9274  |  ONO-7300243  |  S1p receptor agonist 1  |  Ponesimod  |  GNE 2861  |  CYM-5541

品牌介紹:
•   MCE (MedChemExpress) 擁有數百種全球獨家化合物，我們致力于為全球科研客戶提供最新最全的高品質小分子活性化合物；
•   10,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領域；
•   設有專業的實驗中心和嚴格的質控、驗證體系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質檢報告，確保產品的高純度、高品質；
•   產品的生物活性多經各國客戶實驗驗證；
•   Nature, Cell, Science 等多種頂級期刊及制藥專利收錄了MCE客戶的科研成果；
•   專業團隊跟蹤最新的制藥及生命科學研究進展，為您提供全球最新的活性化合物；
•   與世界各大制藥公司及知名科研機構建立了長期的合作。